Biology subjects

Yanai, A.

Publications and source records attributed to Yanai, A..

4 recordsLinked to original sources

bioRxiv2026

Pathogen-specific antimicrobial activity prediction with biological large language model-based methods

Driven by the rise of antimicrobial resistance, antimicrobial peptides (AMPs) have emerged as promising therapeutics capable of targeting multidrug-resistant pathogens. Because identifying AMPs and their specific targets requires costly and labor-intensive wet-lab experiments, in silico methods to prioritize candidates are highly valuable. However, current computational methods often lack pathogen specificity or fail to incorporate crucial targeted proteomic and genomic contexts. To bridge this gap, we developed triAMPh, a robust, zero-shot framework for pathogen-specific peptide bioactivity prediction. triAMPh integrates a heterogeneous graph attention network-based link predictor (HLP), Extreme Gradient Boosting, and a multilayer perceptron trained on features from biological large language models (bLLMs). Our novel HLP constructs a knowledge graph that maps peptides and pathogens as distinct nodes, connected by similarity and bioactivity edges. The model extracts information through semantic traversals, prioritizing neighboring nodes and their biological contexts. Benchmarking shows that triAMPh provides unbiased, peptide- and pathogen-centered zero-shot predictions, matching or outperforming state-of-the-art methods across all metrics except precision. Ultimately, triAMPh offers a powerful computational tool to accelerate wet-lab AMP discovery while demonstrating the capability of bLLMs to capture complex, pathogen-specific bioactivity patterns.

bioinformatics↗

bioRxiv2025

Efficacy and safety evaluation of artificial intelligence-identified antimicrobial peptides for use against avian pathogenic Escherichia coli in the poultry industry

The overuse of antibiotics in both veterinary and human medicine has resulted in the emergence of antibiotic-resistant bacteria, prompting a search for effective alternatives. Antimicrobial peptides (AMP) are short, often cationic, peptide-based molecules with antimicrobial and immunomodulatory activity, which makes them promising alternatives to conventional antibiotics in poultry production. From a prior machine-learning-guided screen of 875 candidate AMPs, 62 exhibited activity against avian pathogenic Escherichia coli (APEC) and low in vitro hemolytic and cytotoxic activity. We selected three lead AMPs from this list (named TeRu4, TeBi1, and PeNi4), and evaluated their in vitro and in vivo efficacy, safety, and immunomodulatory potential for use in poultry farming. In animal experiments, AMPs were administered via in ovo injection on day 18 of embryonic development. In APEC challenge trials, yolk sacs were inoculated with APEC post-hatch to assess early chick mortality, while in pen trials, birds were raised in a commercial production setting for 35 days. For challenged birds, TeBi1 (10 g/egg) significantly reduced bacterial detection in the air sac and pericardium, increased body weight by 50% and reduced cytokine transcript levels by 10-30% on day 7 post hatch. In HD11 chicken macrophage-like cultured cells, TeRu4 (16 g/mL) suppressed lipopolysaccharide (LPS)-induced pro-inflammatory cytokine transcript levels. In pen trials, TeRu4 (20 g/egg) increased the survival probability of female birds by 4.9%, while TeBi1 (20 g/egg) increased the survival probability of all birds by 4.4%, by day 35. Gene expression analysis revealed AMP- and sex-specific cytokine responses. In pen trials, no significant differences were observed in mean weights, feed conversion ratio (FCR), and flock uniformity on day 35. These findings demonstrate that the three selected AMPs are safe antibiotic alternatives that improve survival, modulate immune responses, and maintain normal growth performance in broiler chickens.

microbiology↗

bioRxiv2024

Mining the UniProtKB/Swiss-Prot database forantimicrobial peptides

The ever-growing global health threat of antibiotic resistance is compelling researchers to explore alternatives to conventional antibiotics. Antimicrobial peptides (AMPs) are emerging as a promising solution to fill this need. Naturally occurring AMPs are produced by all forms of life as part of the innate immune system. High-throughput bioinformatics tools have enabled fast and large-scale discovery of AMPs from genomic, transcriptomic, and proteomic resources of selected organisms. Public protein sequence databases, comprising over 200 million records and growing, serve as comprehensive compendia of sequences from a broad range of source organisms. Yet, large-scale in silico probing of those databases for novel AMPs has never been reported. In the present study, we propose an AMP mining workflow to predict novel AMPs from the UniProtKB/Swiss-Prot database using the AMP prediction tool, AMPlify, as its discovery engine. Using this workflow, we identified 8,008 novel putative AMPs from all eukaryotic sequences in the database. Focusing on the practical use of AMPs as suitable antimicrobial agents with applications in the poultry industry, we prioritized 40 of those AMPs based on their similarities to known chicken AMPs in predicted structures. In our tests, 13 out of the 38 successfully synthesized peptides showed antimicrobial activity against Escherichia coli and/or Staphylococcus aureus.

bioinformatics↗

bioRxiv2020

Photoreceptor precursor cell integration into rodent retina after treatment with novel glycopeptide PKX-001

Cell replacement therapy is emerging as an important approach in novel treatments for neurodegenerative diseases. Many problems remain, in particular improvements are needed in the survival of transplanted cells and increasing functional integration into host tissue. These problems arise because of immune rejection, suboptimal precursor cell type, trauma during cell transplantation, toxic compounds released by dying tissues and nutritional deficiencies. We recently developed an ex vivo system to facilitate identification of factors contributing to the death of transplanted neuronal (photoreceptor) and showed 2.8-fold improvement in transplant cell survival after pre-treatment with a novel glycopeptide (PKC-100). In this study we extended these studies to look at cell survival, maturation and functional integration in an in vivo rat model of rhodopsin-mutant retinitis pigmentosa causing blindness. We found that only when human photoreceptor precursor cells (PPCs) were pre-incubated with PKX-100 prior to transplantation, did the cells integrate and mature into cone photoreceptors expressing S-opsin or L/M opsin. In addition, ribbon synapses were observed in the transplanted cells suggesting they were making synaptic connections with the host tissue. Furthermore, optokinetic tracking and electroretinography responses in vivo were significantly improved compared to cell transplants without PKX-100 pre-treatment. These data demonstrate that PKX-100 promotes significant long-term stem cell survival in vivo, providing a platform for further investigation towards the clinical application to repair damaged or diseased retina.

cell biology↗